Compare Moderna, Inc. (MRNA) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Upwork Inc — how do they compare? Moderna, Inc. trades at $221.81 (market cap $78.65B), while Upwork Inc trades at $8.64 (market cap $1.07B). The key difference: Moderna, Inc. is far larger — about 73.5× Upwork Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Upwork Inc for 38 Days on average.
| MRNA | UPWK | |
|---|---|---|
Market Cap | $78.65B | $1.07B |
Volume | 37,373,437 | 2,574,130 |
Sector | Health | Industrials |
52-Week High | $203.46 | $22.11 |
52-Week Low | $22.36 | $7.84 |
Typical Hold Time | 59 Days | 38 Days |
Enterprise Value | $74.80B | $833.01M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Upwork (UPWK) trades at $8.62, up 2.62% today, with a bearish technical signal despite recent earnings beat. The company maintains strong profitability with 77.21% gross margins and 12.93% net income margin, though revenue growth has stalled at $787M for 2026. Recent insider selling and securities fraud investigations create headwinds, while analyst consensus remains positive with a $9.64 price target.
The stock presents a mixed outlook with attractive valuation metrics (P/E 10.99, P/S 1.48) offset by AI-driven competitive threats and declining active clients. Near-term resistance at $9 and support at $8 will be critical, with institutional accumulation by Bank of America providing some stability amid management selling.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
